| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/12/2014 | EP2695618A1 Pharmaceutical composition with synergistic anticonvulsant effect |
| 02/12/2014 | EP2695617A2 Vitamin D glycosides and sulfates for treating intestinal diseases |
| 02/12/2014 | EP2695616A1 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| 02/12/2014 | EP2695615A2 Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation |
| 02/12/2014 | EP2695614A1 Lipoic acid derivatives |
| 02/12/2014 | EP2695613A1 Analgesic |
| 02/12/2014 | EP2695612A1 Use of active substance combinations from urea and carnitine and/or one or more acyl-carnitines used in the treatment and prophylaxis of neurodermatitis and of diabetic foot |
| 02/12/2014 | EP2695611A1 Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof |
| 02/12/2014 | EP2695610A1 Food supplement for improving connective tissue health |
| 02/12/2014 | EP2695609A1 Oral formulations of cytidine analogs and methods of use thereof |
| 02/12/2014 | EP2695605A1 Tranexamic acid composition |
| 02/12/2014 | EP2694968A2 Fungal-derived carbohydrate-conjugated scaffold |
| 02/12/2014 | EP2694652A1 Medicament for liver regeneration and for treatment of liver failure |
| 02/12/2014 | EP2694645A1 Method for increasing the replication capacity of an influenza virus in cultured cells |
| 02/12/2014 | EP2694617A1 Special fluid composition and use thereof |
| 02/12/2014 | EP2694554A1 Methods and compositions for normalization of tumor vasculature by inhibition of loxl2 |
| 02/12/2014 | EP2694521A1 Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| 02/12/2014 | EP2694519A1 Novel heterocyclic compounds as modulators of sphingolipid signaling and uses thereof |
| 02/12/2014 | EP2694518A1 Thieno [2, 3 -d]pyrimidine derivatives and their use to treat arrhythmia |
| 02/12/2014 | EP2694517A1 Protein kinase inhibitors |
| 02/12/2014 | EP2694515A1 Protein kinase inhibitors |
| 02/12/2014 | EP2694513A1 Pyrazolo pyrimidine derivatives |
| 02/12/2014 | EP2694512A1 Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer |
| 02/12/2014 | EP2694511A1 Dihydropyrrolo pyrimidine derivatives as mtor inhibitors |
| 02/12/2014 | EP2694510A1 Imidazopyridazines as akt kinase inhibitors |
| 02/12/2014 | EP2694509A1 Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of tropomyosin- related kinases |
| 02/12/2014 | EP2694508A1 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| 02/12/2014 | EP2694504A2 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h)-ones for the treatment of nervous system disorders and cancer |
| 02/12/2014 | EP2694502A1 Substituted pyrimidinium compounds for combating animal pests |
| 02/12/2014 | EP2694500A1 Substituted imidazopyridines and intermediates thereof |
| 02/12/2014 | EP2694498A1 Aminopyrazine compounds useful as inhibitors of tra kinase |
| 02/12/2014 | EP2694497A1 Novel salts of raltegravir |
| 02/12/2014 | EP2694496A1 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders |
| 02/12/2014 | EP2694495A1 1,4-oxazepines as bace1 and/or bace2 inhibitors |
| 02/12/2014 | EP2694493A1 Method for the preparation of process intermediates for the synthesis of argatroban monohydrate |
| 02/12/2014 | EP2694492A1 Novel compounds as histamine h3 receptor ligands |
| 02/12/2014 | EP2694491A1 Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes |
| 02/12/2014 | EP2694489A1 C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| 02/12/2014 | EP2694488A1 Isoxazole derivatives useful as antibacterial agents |
| 02/12/2014 | EP2694487A1 G-quadruplex stabilising agent |
| 02/12/2014 | EP2694486A1 Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
| 02/12/2014 | EP2694485A1 Combinations of akt inhibitor compounds and vemurafenib, and methods of use |
| 02/12/2014 | EP2694484A1 Pyrimidine derivatives for the treatment of viral infections |
| 02/12/2014 | EP2694481A1 Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
| 02/12/2014 | EP2694478A2 Multifunctional radical quenchers for the treatment of mitochondrial dysfunction |
| 02/12/2014 | EP2694477A1 Anilide-alkyl thioethers as acat inhibitors for the treatment of dermatological diseases |
| 02/12/2014 | EP2694476A1 Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| 02/12/2014 | EP2694475A1 Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof |
| 02/12/2014 | EP2694474A1 4r,5r-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity |
| 02/12/2014 | EP2694472A2 Sulfonamide derivative and use thereof |
| 02/12/2014 | EP2694471A1 Process for the preparation of a sulfated derivative of 3,5-diiodo-o-[3-iodophenyl]-l-tyrosine |
| 02/12/2014 | EP2694470A1 Epoxyeicosatrienoic acid analogs and methods of making and using the same |
| 02/12/2014 | EP2694463A1 Methods of treating central nervous system tumors |
| 02/12/2014 | EP2694160A1 Solid state forms of hiv inhibitor |
| 02/12/2014 | EP2694079A1 Polymers and methods for the treatment of pain |
| 02/12/2014 | EP2694078A1 Selection of hcv treatment |
| 02/12/2014 | EP2694077A1 Method for treating asthenopia |
| 02/12/2014 | EP2694076A1 Nasal formulations of benzodiazepine |
| 02/12/2014 | EP2694075A1 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| 02/12/2014 | EP2694074A1 Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients |
| 02/12/2014 | EP2694073A1 Combinations of akt and mek inhibitor compounds, and methods of use |
| 02/12/2014 | EP2694072A1 Combinations of akt inhibitor compounds and abiraterone, and methods of use |
| 02/12/2014 | EP2694071A1 Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use |
| 02/12/2014 | EP2694070A1 Combinations of akt inhibitor compounds and erlotinib, and methods of use |
| 02/12/2014 | EP2694069A1 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| 02/12/2014 | EP2694068A1 Pyridopyrazine derivatives and their use |
| 02/12/2014 | EP2694067A1 Pyridopyrazine derivatives and their use |
| 02/12/2014 | EP2694066A1 Methods and compositions for treating parkinson's disease |
| 02/12/2014 | EP2694065A2 Treatment regimens |
| 02/12/2014 | EP2694064A1 Methods and compositions for treating neurodegenerative diseases |
| 02/12/2014 | EP2694063A1 Short -acting dihydropyridines (clevidipine) for use in reducing stroke damage |
| 02/12/2014 | EP2694062A2 Methods for treating cancer |
| 02/12/2014 | EP2694061A2 Compounds for use as therapeutic agents affecting p53 expression and/or activity |
| 02/12/2014 | EP2694060A1 Substituted 3-(1h-benzo{d}imidazol-2-yl)-1h-indazole-analogs as inhibitors of the pdk1 kinase |
| 02/12/2014 | EP2694059A2 Small molecule inhibitors of xbp1 splicing |
| 02/12/2014 | EP2694058A2 New indolinone protein kinase inhibitors |
| 02/12/2014 | EP2694057A1 Lipoxygenase inhibitors |
| 02/12/2014 | EP2694056A1 Therapeutic treatment |
| 02/12/2014 | EP2694055A1 Taxane and abeo-taxane analogs |
| 02/12/2014 | EP2694054A1 Zinc n-acetyl taurinate for the treatment of prostate cancer |
| 02/12/2014 | EP2694053A2 Selective androgen receptor modulators for treating diabetes |
| 02/12/2014 | EP2694052A1 Sn-1(3) monoacylglycerides and lipid absorption |
| 02/12/2014 | EP2694051A1 Use of l-carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function |
| 02/12/2014 | EP2694050A1 Tapentadol for treating pain associated with trigeminal neuralgia |
| 02/12/2014 | EP2694049A1 Tapentadol for preventing chronification of pain |
| 02/12/2014 | EP2694048A2 Ophthalmic treatments |
| 02/12/2014 | EP2694047A1 Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same |
| 02/12/2014 | EP2694046A1 Methods and pharmaceutical compositions for inhibiting influenza viruses replication |
| 02/12/2014 | EP2694045A1 New combination comprising n-acetyl-l-cysteine and its use |
| 02/12/2014 | EP2694044A1 Synergistic compositions and methods |
| 02/12/2014 | EP2694043A1 Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
| 02/12/2014 | EP2694040A2 Osmotic mediated release synthetic nanocarriers |
| 02/12/2014 | EP2694039A1 Solid preparation |
| 02/12/2014 | EP2694038A2 Pharmaceutical composition |
| 02/12/2014 | EP2694037A1 Formulations comprising 2 -amino- 2- [2- (4 - octylphenyl) ethyl]propane -1, 3 - diol |
| 02/12/2014 | EP2694036A1 Pharmaceutical composition comprising fesoterodine |
| 02/12/2014 | EP2694033A1 The treatment of viral infections |
| 02/12/2014 | EP2694021A2 Healing composition for topical application |
| 02/12/2014 | EP2693884A1 Composition comprising antimicrobial metal ions and a quaternary cationic surfactant |
| 02/12/2014 | EP2693882A1 Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |